Evaluate Low Doses of AEGR-733 on Hepatic Fat Accumulation by MRS
Recruiting in Palo Alto (17 mi)
+14 other locations
Age: 18+
Sex: Any
Travel: May Be Covered
Time Reimbursement: Varies
Trial Phase: Phase 2
Waitlist Available
Sponsor: Aegerion Pharmaceuticals, Inc.
Prior Safety Data
Trial Summary
What is the purpose of this trial?
To determine safety and effectiveness of low-dose therapeutic AEGR-733 +/- atorvastatin, ezetimibe or fenofibrate (compared to placebo) on liver fat accumulation measured by Magnetic Resonance Spectroscopy
Research Team
WS
William Sasiela, PhD
Principal Investigator
Aegerion Pharmaceuticals, Inc.
Eligibility Criteria
Inclusion Criteria
LDL-C between 100 and 190 mg/dL
Hepatic fat under 6.2% per MRS
Treatment Details
Interventions
- AEGR-733 (Other)
- AEGR-733 and atorvastatin (Other)
- AEGR-733 and ezetimibe (Other)
- AEGR-733 and fenofibrate (Other)
- Placebo (Other)
Participant Groups
8Treatment groups
Active Control
Placebo Group
Group I: 4Active Control1 Intervention
7.5 mg AEGR-733
Group II: 2Active Control1 Intervention
2.5 mg AEGR-733
Group III: 3Active Control1 Intervention
5 mg AEGR-733
Group IV: 5Active Control1 Intervention
10 mg AEGR-733
Group V: 7Active Control1 Intervention
5 mg AEGR-733 + 145 mg fenofibrate
Group VI: 6Active Control1 Intervention
5 mg AEGR-733 + 20 mg atorvastatin
Group VII: 8Active Control1 Intervention
5 mg AEGR-733 + 10 mg ezetimibe
Group VIII: 1Placebo Group1 Intervention
Placebo
Find a Clinic Near You
Research Locations NearbySelect from list below to view details:
Sterling Research GroupCincinnati, OH
University of PennsylvaniaPhiladelphia, PA
Scripps ClinicSan Diego, CA
Radiant ResearchSanta Rosa, CA
More Trial Locations
Loading ...
Who Is Running the Clinical Trial?
Aegerion Pharmaceuticals, Inc.
Lead Sponsor
Trials
20
Patients Recruited
1,630,000+